LONDON, July 20- Nine months after the world’s first malaria vaccine was recommended, the international vaccine alliance Gavi invited countries to apply for financial support to roll out the jab, mainly targeting young children in Africa.
The World Health Organization endorsed GSK Plc’s (GSK.L) four-dose Mosquirix shot in October last year, saying it could save thousands of lives.
Now Gavi, which has $155.7 million available over 2022-2025 for the initial roll-out of the vaccine, has invited countries to apply for funding and support to distribute the shot.
More News: WHO reports 14,000 cases of monkeypox globally, five deaths in Africa Read more…
It is a step forward for the vaccine, which has taken decades to develop. Malaria, on average, kills a child every minute.
However, a recent Reuters investigation found that the roll-out is expected to start slowly, with supply falling far below the vast demand for several years. read more
Ghana, Kenya, and Malawi – African nations involved in pilot programs using the vaccine – can apply by September to broaden their use of the shot. Other countries can apply by the end of this year, Gavi said in a statement.
More news: Italy battles wildfires as hundreds evacuated in Tuscany Read more…
“The work towards a malaria vaccine has been long and hard,” said Seth Berkley, chief executive of Gavi. Alongside the existing interventions like bed nets, Berkley said he hoped the new tool would now “allow us to save more lives in countries hit hardest by this killer disease.”